Interpersonal behavior and experience of patients with chronic depression or borderline personality disorder: Examining the long-term effectiveness of disorder-specific psychotherapy regarding biological (oxytocin), (epi-)genetic and clinical variables

Interpersonal behavior and experience of patients with chronic depression or borderline personality disorder: Examining the long-term effectiveness of disorder-specific psychotherapy regarding biological (oxytocin), (epi-)genetic and clinical variables - CBASP-DBT-Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00019821

Enrollment

500

Registered

2020-05-28

Start date

2018-05-18

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DSM-5: 300.4 Persistent depressive disorder DSM-5 301.83 borderline personality disorder F33 F34.1 F60.31

Interventions

Group 1: Patients take part in a ten week psychotherapy program CBASP or DBT with assessment at the beginning and after ten weeks, after six months and after twelve months. Group 2: Healthy controls a

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Participation in the DBT-program or in the CBASP program for patients with BPD or CD (according to DSM-5). Psychologically and physiologically healthy participants, without any psychiatric illness in the past (participant does not fulfill any diagnosis in the SKID-5-CV and does not fulfill more than three criteria for any of the personality disorders in the SKID-5-PD).

Exclusion criteria

Exclusion criteria: Patient groups: - Acute suicidal ideation - Any unstable or not sufficiently treated accompanying somatic disorder (e.g. hypothyroidism orhypertonia), including acute or chronic infections and autoimmune diseases - Pregnancy Control group: - Any unstable or not sufficiently treated concomitant somatic disorders (e.g. hypothyroidism or hypertonia), including acute or chronic infections and autoimmune diseases - Previous participation at any study including the cyberball paradigm - Current or previous (within the last 10 years) intake of psychiatric drugs (exception: benzodiazepine, z-medication) - Pregnancy and breastfeeding period - Previous psychiatric treatment - Previous psychotherapeutic treatment (within the last 10 years) - Excessive smoking (> 1,5 packages/day) - Noticeable score on the BDI (> 12) and on the SKID-5-CV/PD-Screenings

Design outcomes

Primary

Measure	Time frame
Change in MADRS-Score / BDI-II / BSL-23 after ten weeks	—

Secondary

Measure	Time frame
Change in depressive and borderline symptoms, interpersonal problems and interpersonal impact, life quality, loneliness, social network index, attachment style, working alliance, plasma oxytocin levels, epigenetic regulation of oxytocin after 6 and 12 months.	—

Countries

Germany

Contacts

Public ContactFrank Padberg

Klinik für Psychiatrie und Psychotherapie, Klinikum der Universität München

frank.padberg@med.uni-muenchen.de089/4400-53358

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 8, 2026